Asked by: Darren Paffey (Labour - Southampton Itchen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the Medicines and Healthcare products Regulatory Agency on the potential impact (a) emerging diagnostic technologies and (b) breath testing on (i) detection and (ii) survival rates for people for pancreatic cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not had discussions with the Medicines and Healthcare products Regulatory Agency on this topic, however we remain committed to improving survival rates for people with all cancers including pancreatic cancer.
The National Cancer Plan for England will include further details on how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates.
Asked by: Josh Fenton-Glynn (Labour - Calder Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an estimate of the average time between the (a) onset of symptoms and (b) formal diagnosis for patients with (i) lung, (ii) pancreatic, (iii) liver, (iv) brain, (v) oesophageal and (vi) stomach cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is supporting the National Health Service to meet the Faster Diagnosis Standard (FDS), for 75% of patients to be diagnosed or have cancer ruled out within 28 days of being referred urgently by their general practitioner (GP) for suspected cancer. NHS England collects and publishes monthly FDS performance data nationally and for individual cancer groups. Data is not available from the time of the onset of symptoms, but from referral.
To achieve the FDS, NHS England rolled out public awareness campaigns of cancer signs and symptoms, streamlined referral routes for different cancer types, and is increasing the availability of diagnostic capacity through the roll-out of more community diagnostic centres.
NHS England has also achieved full roll out of non-specific symptom pathways for patients who present with vague and non-site-specific symptoms which do not clearly align to a tumour type.
The NHS is also taking crucial steps to improve lung cancer outcomes for patients across England, including the roll out of the Lung Cancer Screening Programme, designed to identify cancer at an earlier stage, and which is aimed at high-risk individuals or people with a history of smoking between the ages of 55 and 74 years old.
Additionally, we set out expectations for renewed focus on cancer targets in the Elective Reform plan, published on 6 January 2025. We asked systems and providers to identify local opportunities in both community diagnostic centres and hospital based diagnostic services to improve performance against the FDS, to reduce the number of patients waiting too long for a confirmed diagnosis of cancer.
As part of developing the forthcoming National Cancer Plan for England, the Department has been working with members of the Less Survivable Cancers Taskforce to identify how to improve diagnosis, treatment, and outcomes for less survivable cancers, which includes lung, pancreatic, liver, brain, oesophageal, and stomach cancer.
Asked by: Josh Fenton-Glynn (Labour - Calder Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help reduce the time taken to diagnose (a) lung, (b) pancreatic, (c) liver, (d) brain, (e) oesophageal and (f) stomach cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is supporting the National Health Service to meet the Faster Diagnosis Standard (FDS), for 75% of patients to be diagnosed or have cancer ruled out within 28 days of being referred urgently by their general practitioner (GP) for suspected cancer. NHS England collects and publishes monthly FDS performance data nationally and for individual cancer groups. Data is not available from the time of the onset of symptoms, but from referral.
To achieve the FDS, NHS England rolled out public awareness campaigns of cancer signs and symptoms, streamlined referral routes for different cancer types, and is increasing the availability of diagnostic capacity through the roll-out of more community diagnostic centres.
NHS England has also achieved full roll out of non-specific symptom pathways for patients who present with vague and non-site-specific symptoms which do not clearly align to a tumour type.
The NHS is also taking crucial steps to improve lung cancer outcomes for patients across England, including the roll out of the Lung Cancer Screening Programme, designed to identify cancer at an earlier stage, and which is aimed at high-risk individuals or people with a history of smoking between the ages of 55 and 74 years old.
Additionally, we set out expectations for renewed focus on cancer targets in the Elective Reform plan, published on 6 January 2025. We asked systems and providers to identify local opportunities in both community diagnostic centres and hospital based diagnostic services to improve performance against the FDS, to reduce the number of patients waiting too long for a confirmed diagnosis of cancer.
As part of developing the forthcoming National Cancer Plan for England, the Department has been working with members of the Less Survivable Cancers Taskforce to identify how to improve diagnosis, treatment, and outcomes for less survivable cancers, which includes lung, pancreatic, liver, brain, oesophageal, and stomach cancer.
Asked by: Josh Fenton-Glynn (Labour - Calder Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce the time taken to diagnose (a) cancers that present with (i) vague and (ii) non-specific symptoms and (b) pancreatic cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is supporting the National Health Service to meet the Faster Diagnosis Standard (FDS), for 75% of patients to be diagnosed or have cancer ruled out within 28 days of being referred urgently by their general practitioner (GP) for suspected cancer. NHS England collects and publishes monthly FDS performance data nationally and for individual cancer groups. Data is not available from the time of the onset of symptoms, but from referral.
To achieve the FDS, NHS England rolled out public awareness campaigns of cancer signs and symptoms, streamlined referral routes for different cancer types, and is increasing the availability of diagnostic capacity through the roll-out of more community diagnostic centres.
NHS England has also achieved full roll out of non-specific symptom pathways for patients who present with vague and non-site-specific symptoms which do not clearly align to a tumour type.
The NHS is also taking crucial steps to improve lung cancer outcomes for patients across England, including the roll out of the Lung Cancer Screening Programme, designed to identify cancer at an earlier stage, and which is aimed at high-risk individuals or people with a history of smoking between the ages of 55 and 74 years old.
Additionally, we set out expectations for renewed focus on cancer targets in the Elective Reform plan, published on 6 January 2025. We asked systems and providers to identify local opportunities in both community diagnostic centres and hospital based diagnostic services to improve performance against the FDS, to reduce the number of patients waiting too long for a confirmed diagnosis of cancer.
As part of developing the forthcoming National Cancer Plan for England, the Department has been working with members of the Less Survivable Cancers Taskforce to identify how to improve diagnosis, treatment, and outcomes for less survivable cancers, which includes lung, pancreatic, liver, brain, oesophageal, and stomach cancer.
Asked by: Patrick Hurley (Labour - Southport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of establishing a national multi-cancer case-finding initiative to identify people at higher risk of (a) pancreatic and (b) other less survivable cancers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England is working on case-finding approaches for less survivable cancers, where the evidence suggests this is appropriate. This includes a public-facing Family History Checker, which enables people and their families affected by pancreatic cancer to self-assess if they may inherit risk. Individuals identified as being at risk are referred directly to the European Registry of Hereditary Pancreatic Diseases research trial, which aims to understand inherited conditions of the pancreas. Referrals to the trial can be made by any healthcare professional across all health sectors or by individuals via self-referral, contributing to a centralised approach to case-finding.
The National Disease Registration Service is developing a National Inherited Cancer Predisposition Register (NICPR), which launched on 30 June. The NICPR looks at a wide range of cancers for which there is an increased inherited risk, including for less survivable cancers. It aims to identify high-risk individuals who are eligible for targeted screening and surveillance and will act as an electronic referral route into national screening programmes where these exist.
Asked by: Ruth Jones (Labour - Newport West and Islwyn)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to collaborate with (a) academic institutions, (b) industry, and (c) research charities in rolling out new diagnostic tools for pancreatic cancer across primary care pathways.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
While cancer, including pancreatic cancer, is not diagnosed in primary care, there are initiatives to improve the identification of cancer symptoms in primary care. This includes ‘Jess’s Rule’, which supports clinicians to rethink their assessments when patients have presented three times with the same symptoms or concerns. Jess’s Rule was developed through a process of engagement with leading clinicians and charities.
NHS England is working with Pancreatic Cancer UK to develop a public-facing Family History Checker, which enables people, and their families, affected by pancreatic cancer to self-assess if they have inherited risk. People identified of being at risk are referred directly to the European Registry of Hereditary Pancreatic Diseases research trail, which aims to understand inherited conditions of the pancreas. Referrals to the trail can be made by any healthcare professional across all health sectors, including primary care, or by individuals via self-referral.
Research continues to play a vital role, with National Institute for Health and Care Research (NIHR) infrastructure supporting dozens of studies annually in partnership with industry and charities. This is also a vital part of improving diagnosis and treatment for cancer. The NIHR has invested £4.4 million to directly funded pancreatic cancer research from 2018/19 to 2023/24. These investments are pivotal to informing efforts to improve cancer prevention, treatment and outcomes.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of commissioning arrangements for (a) Molecular Radiotherapy, (b) Stereotactic Ablative Body Radiotherapy and (c) Systemic Anti-Cancer Therapies.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service delivers a range of treatments for cancer, with expert clinicians working with patients to determine the most appropriate option. The Government is working with NHS England to ensure that the most effective treatments are available to patients across the country when they need them.
Stereotactic ablative body radiotherapy (SABR) is routinely available to treat several types of cancer, including some types of lung cancer, pancreatic cancer, and liver cancer. Every NHS trust that is commissioned to provide radiotherapy services in England can offer SABR. However, not all cancer types can be treated with SABR in every radiotherapy service, because some trusts may not host the relevant specialist multi-disciplinary team.
No assessment has been made of the potential for systemic anti-cancer therapies to be delivered via primary care in the community or at home. However, in line with the Government’s Health Mission shift from hospital to community, the 10-Year Health Plan committed to deliver more urgent care in the community, in people’s homes, or through neighbourhood health centres by 2035.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential for systemic anti-cancer therapies to be delivered via primary care in the community or at home.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service delivers a range of treatments for cancer, with expert clinicians working with patients to determine the most appropriate option. The Government is working with NHS England to ensure that the most effective treatments are available to patients across the country when they need them.
Stereotactic ablative body radiotherapy (SABR) is routinely available to treat several types of cancer, including some types of lung cancer, pancreatic cancer, and liver cancer. Every NHS trust that is commissioned to provide radiotherapy services in England can offer SABR. However, not all cancer types can be treated with SABR in every radiotherapy service, because some trusts may not host the relevant specialist multi-disciplinary team.
No assessment has been made of the potential for systemic anti-cancer therapies to be delivered via primary care in the community or at home. However, in line with the Government’s Health Mission shift from hospital to community, the 10-Year Health Plan committed to deliver more urgent care in the community, in people’s homes, or through neighbourhood health centres by 2035.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, in which NHS trusts Stereotactic Ablative Body Radiotherapy is available in England .
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service delivers a range of treatments for cancer, with expert clinicians working with patients to determine the most appropriate option. The Government is working with NHS England to ensure that the most effective treatments are available to patients across the country when they need them.
Stereotactic ablative body radiotherapy (SABR) is routinely available to treat several types of cancer, including some types of lung cancer, pancreatic cancer, and liver cancer. Every NHS trust that is commissioned to provide radiotherapy services in England can offer SABR. However, not all cancer types can be treated with SABR in every radiotherapy service, because some trusts may not host the relevant specialist multi-disciplinary team.
No assessment has been made of the potential for systemic anti-cancer therapies to be delivered via primary care in the community or at home. However, in line with the Government’s Health Mission shift from hospital to community, the 10-Year Health Plan committed to deliver more urgent care in the community, in people’s homes, or through neighbourhood health centres by 2035.
Asked by: Patrick Hurley (Labour - Southport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to monitor people with inherited cancer risk for less survivable cancers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is supporting NHS England with initiatives to monitor people with an inherited risk of less survivable cancers. The 10-Year Health Plan commits to expanding genomic testing for inherited causes of major diseases to allow for earlier detection and intervention, including for cancer.
In June 2024, NHS England launched the national NHS Jewish BRCA Testing Programme to identify cancer earlier for people with Jewish ancestry, including genetic testing for patients diagnosed historically with an eligible breast or ovarian cancer. BRCA genetic mutations carry a risk of developing other cancers such as pancreatic cancer.
For pancreatic cancer, which the latest data showed has the lowest survivable rate with inherited risk, NHS England is working with The European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer, Pancreatic Cancer UK, and Cancer Alliances to improve surveillance pathways and access to surveillance for people with inherited high risk of pancreatic cancer.
In June 2025, NHS England launched a new initiative for general practices to analyse patient records to identify people aged over 60 years old who have the key early warning signs and symptoms of pancreatic cancer including diabetes and sudden weight loss. Additionally, Pancreatic Cancer UK has launched the Family History Checker, supported by NHS England. The tool allows people, and their families, affected by pancreatic cancer to self-assess if they have inherited risk.
Furthermore, improving the early detection of cancers, including less survival cancers, is also a priority for the National Cancer Plan, which will be published later this year.